- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06886360
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
March 19, 2025 updated by: Dr. Falk Pharma GmbH
An Open-label Study of Patients with Primary Sclerosing Cholangitis (PSC) Treated with Norucholic Acid Tablets
Open-label, multi-center, phase III trial.
Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Stiess, PhD
- Phone Number: +497611514 Ext. 0
- Email: zentrale@drfalkpharma.de
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- Signed informed consent.
- Males or females ≥ 18 years.
- Patient has previously been diagnosed with PSC, has participated in the previous NUC 5/PSC trial and has completed the DBE phase with Visit 22, or has prematurely terminated the DBE phase before this trial has been started, or has prematurely terminated the DBE phase after this trial has been started, under the condition that the premature termination was due to lack of efficacy*. (*Lack of efficacy as defined in the NUC-5/PSC trial.)
Exclusion Criteria:
- History or presence of chronic alcoholic consumption (daily consumption > 30 g in men, > 20 g in women).
- Patients who discontinued study participation in NUC-5/PSC due to an AE possibly caused by the study drug.
- Liver Cirrhosis or any cirrhosis-related symptoms which in the opinion of the investigator may affect the patient's safety.
- History of liver transplantation or patient listed for transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: norucholic acid 1500 mg/day
3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg
|
500 mg norucholic acid film-coated tablets; 3 tablets/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of serious treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of severe treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of adverse drug reactions
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of unexpected treatment emergent adverse events
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of treatment emergent adverse events leading to study withdrawal
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
|
Occurrence of adverse events leading to death
Time Frame: 72 weeks from enrollment to end of treatment
|
72 weeks from enrollment to end of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Trauner, MD, Medical University of Vienna, dept. of Internal Medicine III
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2025
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Study Registration Dates
First Submitted
March 14, 2025
First Submitted That Met QC Criteria
March 19, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
March 19, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUT-022/PSC
- 2024-514292-18-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
It is not decided which data will be made available.
A time frame cannot be indicated yet.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.